Skip to content

Study · Randomized controlled trial · n = 98 · 2006

3 results

Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C.

Chien RN, Lin CY, Yeh CT, Liaw YF

Journal of viral hepatitis1 Dec 2006Cited by 15 (Europe PMC)

PMID17109685 (opens in a new tab)DOI10.1111/j.1365-2893.2006.00761.x (opens in a new tab)PepBankPUB-17109685
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with chronic hepatitis B, thymosin alpha‑1 treatment was an independent factor associated with complete response in stepwise logistic regression (OR 12.045, 95% CI 2.220-65.354, P = 0.004).

    In plain wordsIn adults with chronic hepatitis B, thymosin alpha‑1 treatment was linked to a higher chance of complete response than no treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseComplete response, independent association with thymosin alpha-1 treatment
    Study

    n = 98

    Comparator
    Untreated control (T0 group)
    Outcome group
    Antiviral activity · Liver
    Studied dose
    1.6 mg two times a week · 26 or 52 weeksAs given in this study (human).

    Measurements

    OR
    12.045
    complete response, thymosin alpha-1 treatment

    Source sentences

    Summary
    Talpha-1 treatment (OR, 12.045; 95% CI, 2.220-65.354; P = 0.004
    1 context sentence
    Summary · context
    It consisted 98 patients with chronic hepatitis B randomly allocating to three groups: (i) T6 group (n = 32) received a 26-week course of Talpha1 1.6 mg two times a week; (ii) T12 group (n = 34) received the same regimen as T6 group, but Talpha1 therapy extended for 52 weeks; (iii) T0 group (n = 32)…
  2. 02HumanObservational studyEfficacy outcome

    In adults with chronic hepatitis B given thymosin alpha‑1, the complete response rate was higher in patients with genotype B than with genotype C (52% vs 24%, P = 0.036).

    In plain wordsIn adults with chronic hepatitis B given thymosin alpha‑1, response was more frequent in those with HBV genotype B than with genotype C.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableComplete response by HBV genotype (B vs C)
    Study

    n: not reported in source

    Comparator
    Genotype C
    Outcome group
    Antiviral activity · Liver
    Studied dose
    1.6 mg two times a week · 26 or 52 weeksAs given in this study (human).

    Measurements

    Complete response
    52%
    genotype B
    Complete response
    24%
    genotype C

    Source sentences

    Summary
    The complete response of Talpha-1 therapy was higher in patients with genotype B compared to patients with genotype C (52%vs 24%; P = 0.036
    1 context sentence
    Summary · context
    It consisted 98 patients with chronic hepatitis B randomly allocating to three groups: (i) T6 group (n = 32) received a 26-week course of Talpha1 1.6 mg two times a week; (ii) T12 group (n = 34) received the same regimen as T6 group, but Talpha1 therapy extended for 52 weeks; (iii) T0 group (n = 32)…
  3. 03HumanObservational studyEfficacy outcome

    In adults with chronic hepatitis B given thymosin alpha‑1, the complete response rate was higher in patients with a precore mutation (64% vs 19%, P = 0.002).

    In plain wordsIn adults with chronic hepatitis B given thymosin alpha‑1, response was more frequent in those with a precore mutation than in those without.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableComplete response by precore mutation
    Study

    n: not reported in source

    Comparator
    No precore mutation
    Outcome group
    Antiviral activity · Liver
    Studied dose
    1.6 mg two times a week · 26 or 52 weeksAs given in this study (human).

    Measurements

    Complete response
    64%
    precore mutation
    Complete response
    19%
    no precore mutation

    Source sentences

    Summary
    The complete response of Talpha-1 therapy was higher in patients with genotype B compared to patients with genotype C (52%vs 24%; P = 0.036) and in patients with precore mutation (64%vs 19%; P = 0.002).
    1 context sentence
    Summary · context
    It consisted 98 patients with chronic hepatitis B randomly allocating to three groups: (i) T6 group (n = 32) received a 26-week course of Talpha1 1.6 mg two times a week; (ii) T12 group (n = 34) received the same regimen as T6 group, but Talpha1 therapy extended for 52 weeks; (iii) T0 group (n = 32)…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.